申请人:HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GmbH
公开号:US10188682B2
公开(公告)日:2019-01-29
The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
本发明涉及一种抑制 MKK4 活性的化合物作为治疗肝功能受损患者的药物的用途,涉及一种化合物作为治疗肝衰竭(包括急性/严重或慢性肝衰竭)和/或增加患者肝组织再生的药物的用途。